ALNY — Alnylam Pharmaceuticals Share Price
Last trade - 00:00- $18.70bn
- $17.28bn
- $1.83bn
- 83
- 13
- 34
- 39
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 445.85 | ||
| Price to Sales | 10.23 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -9.86% | ||
| Return on Equity | n/a | ||
| Operating Margin | -15.43% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 219.75 | 492.85 | 844.29 | 1,037.42 | 1,828.29 | 1,852.82 | 2,329.17 | 89.45% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Alnylam Pharmaceuticals, Inc. is a clinical-stage company. The Company is engaged in developing mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead product candidate, Descartes-08, is an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA). Descartes-08 targets BCMA, which exists on the surface of long-lived plasma cells and plasmacytoid dendritic cells. Descartes-08 is in Phase IIb clinical development for patients with generalized myasthenia gravis (MG). Its other product candidate includes Descartes-15 and Descartes-33. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.
Directors
- Michael Bonney CHM (63)
- Akshay Vaishnaw PRE (59)
- Yvonne Greenstreet CEO (58)
- Jeffrey Poulton CFO (53)
- Kasha Witkos SVP
- Amy Schulman LED (60)
- Dennis Ausiello IND (75)
- Olivier Brandicourt IND (65)
- Marsha Fanucci IND (67)
- Margaret Hamburg IND (65)
- Steven Paul IND (70)
- David Pyott IND (68)
- Colleen Reitan IND (61)
- Phillip Sharp IND (76)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- May 8th, 2003
- Public Since
- May 28th, 2004
- No. of Shareholders
- 24
- No. of Employees
- 2,100
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 125,933,946
- Address
- 675 W Kendall St, CAMBRIDGE, 02142-1168
- Web
- https://www.alnylam.com/
- Phone
- +1 6175518200
- Auditors
- PricewaterhouseCoopers LLP
Latest News for ALNY
Upcoming Events for ALNY
Q1 2024 Alnylam Pharmaceuticals Inc Earnings Release
Alnylam Pharmaceuticals Inc Annual Shareholders Meeting
Alnylam Pharmaceuticals Inc Annual Shareholders Meeting
Q2 2024 Alnylam Pharmaceuticals Inc Earnings Release
Similar to ALNY
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 19:02 UTC, shares in Alnylam Pharmaceuticals are trading at $148.50. This share price information is delayed by 15 minutes.
Shares in Alnylam Pharmaceuticals last closed at $148.50 and the price had moved by -28.38% over the past 365 days. In terms of relative price strength the Alnylam Pharmaceuticals share price has underperformed the S&P500 Index by -42.16% over the past year.
The overall consensus recommendation for Alnylam Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Alnylam Pharmaceuticals does not currently pay a dividend.
Alnylam Pharmaceuticals does not currently pay a dividend.
Alnylam Pharmaceuticals does not currently pay a dividend.
To buy shares in Alnylam Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $148.50, shares in Alnylam Pharmaceuticals had a market capitalisation of $18.70bn.
Here are the trading details for Alnylam Pharmaceuticals:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ALNY
Based on an overall assessment of its quality, value and momentum Alnylam Pharmaceuticals is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Alnylam Pharmaceuticals is $222.68. That is 49.95% above the last closing price of $148.50.
Analysts covering Alnylam Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$4.11 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Alnylam Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -24.6%.
As of the last closing price of $148.50, shares in Alnylam Pharmaceuticals were trading -15.21% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Alnylam Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $148.50.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Alnylam Pharmaceuticals' management team is headed by:
- Michael Bonney - CHM
- Akshay Vaishnaw - PRE
- Yvonne Greenstreet - CEO
- Jeffrey Poulton - CFO
- Kasha Witkos - SVP
- Amy Schulman - LED
- Dennis Ausiello - IND
- Olivier Brandicourt - IND
- Marsha Fanucci - IND
- Margaret Hamburg - IND
- Steven Paul - IND
- David Pyott - IND
- Colleen Reitan - IND
- Phillip Sharp - IND